JP6947649B2 - 複合治療のためのｖｅｇｆｒ−２標的化ｄｎａワクチン - Google Patents

複合治療のためのｖｅｇｆｒ−２標的化ｄｎａワクチン Download PDF

Info

Publication number
JP6947649B2
JP6947649B2 JP2017565248A JP2017565248A JP6947649B2 JP 6947649 B2 JP6947649 B2 JP 6947649B2 JP 2017565248 A JP2017565248 A JP 2017565248A JP 2017565248 A JP2017565248 A JP 2017565248A JP 6947649 B2 JP6947649 B2 JP 6947649B2
Authority
JP
Japan
Prior art keywords
salmonella
pharmaceutical composition
protein
seq
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017565248A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018517419A (ja
JP2018517419A5 (enExample
Inventor
リュベナウ ハインツ
リュベナウ ハインツ
Original Assignee
バクシム アクチェンゲゼルシャフト
バクシム アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バクシム アクチェンゲゼルシャフト, バクシム アクチェンゲゼルシャフト filed Critical バクシム アクチェンゲゼルシャフト
Publication of JP2018517419A publication Critical patent/JP2018517419A/ja
Publication of JP2018517419A5 publication Critical patent/JP2018517419A5/ja
Application granted granted Critical
Publication of JP6947649B2 publication Critical patent/JP6947649B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2017565248A 2015-06-18 2016-06-16 複合治療のためのｖｅｇｆｒ−２標的化ｄｎａワクチン Active JP6947649B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15001803 2015-06-18
EP15001803.4 2015-06-18
PCT/EP2016/001004 WO2016202459A1 (en) 2015-06-18 2016-06-16 Vegfr-2 targeting dna vaccine for combination therapy

Publications (3)

Publication Number Publication Date
JP2018517419A JP2018517419A (ja) 2018-07-05
JP2018517419A5 JP2018517419A5 (enExample) 2019-05-30
JP6947649B2 true JP6947649B2 (ja) 2021-10-13

Family

ID=53476620

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017565248A Active JP6947649B2 (ja) 2015-06-18 2016-06-16 複合治療のためのｖｅｇｆｒ−２標的化ｄｎａワクチン

Country Status (19)

Country Link
US (2) US10905752B2 (enExample)
EP (2) EP3310379B1 (enExample)
JP (1) JP6947649B2 (enExample)
KR (2) KR20250024816A (enExample)
CN (1) CN107995868B (enExample)
AU (1) AU2016278588B2 (enExample)
BR (1) BR112017027378A2 (enExample)
CA (1) CA2989247C (enExample)
DK (1) DK3310379T3 (enExample)
ES (2) ES2994561T3 (enExample)
HU (1) HUE046631T2 (enExample)
IL (1) IL256076A (enExample)
LT (1) LT3310379T (enExample)
MX (1) MX2017016183A (enExample)
PL (2) PL3310379T3 (enExample)
RU (1) RU2018101722A (enExample)
SI (1) SI3310379T1 (enExample)
WO (1) WO2016202459A1 (enExample)
ZA (1) ZA201708439B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019112977A (ru) * 2016-11-04 2020-12-04 Факсимм Аг Днк-вакцина, нацеленная на wt1, для комбинированной терапии
JP7712060B2 (ja) 2017-02-17 2025-07-23 バクシム アクチェンゲゼルシャフト 新規ｖｅｇｆｒ－２ターゲット免疫療法アプローチ
JP7247097B2 (ja) * 2017-03-17 2023-03-28 バクシム アクチェンゲゼルシャフト がん免疫療法のための新規ｐｄ－ｌ１標的ｄｎａワクチン
CA3109430A1 (en) * 2018-09-05 2020-03-12 Vaximm Ag Neoantigen targeting dna vaccine for combination therapy
KR20220128638A (ko) * 2020-01-13 2022-09-21 백심 아게 항생제와 조합되는 살모넬라-기반의 dna 백신
EP3922255A1 (en) * 2020-06-10 2021-12-15 Prokarium Limited Cancer therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094410B2 (en) 2002-03-02 2006-08-22 The Scripps Research Institute DNA vaccine against proliferating endothelial cells and methods of use thereof
NO337687B1 (no) 2011-07-08 2016-06-06 Norsk Elektro Optikk As Hyperspektralt kamera og metode for å ta opp hyperspektrale data
US9493738B2 (en) 2011-12-22 2016-11-15 Vaximm Ag Method for producing high yield attenuated Salmonella strains
EP3603664A1 (en) * 2012-07-05 2020-02-05 Vaximm AG Dna vaccine for use in pancreatic cancer patients
BR112015006176B1 (pt) * 2012-09-21 2023-04-18 Intensity Therapeutics, Inc Uso de um agente terapêutico e de um agente de intensificação de permeação intracelular
US9974845B2 (en) * 2013-02-22 2018-05-22 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
ES2675020T3 (es) 2013-04-25 2018-07-05 Vaximm Ag Vectores basados en Salmonella para inmunoterapia del cáncer dirigida al gen WT1 del tumor de Wilms
SG11201604911VA (en) * 2013-12-18 2016-07-28 Vaximm Gmbh Novel msln targeting dna vaccine for cancer immunotherapy
JP7712060B2 (ja) * 2017-02-17 2025-07-23 バクシム アクチェンゲゼルシャフト 新規ｖｅｇｆｒ－２ターゲット免疫療法アプローチ
JP7247097B2 (ja) * 2017-03-17 2023-03-28 バクシム アクチェンゲゼルシャフト がん免疫療法のための新規ｐｄ－ｌ１標的ｄｎａワクチン

Also Published As

Publication number Publication date
DK3310379T3 (da) 2019-12-16
CN107995868B (zh) 2021-07-13
PL3310379T3 (pl) 2020-03-31
US20180250345A1 (en) 2018-09-06
EP3310379A1 (en) 2018-04-25
HUE046631T2 (hu) 2020-03-30
CN107995868A (zh) 2018-05-04
PL3626262T3 (pl) 2025-02-17
KR20250024816A (ko) 2025-02-19
JP2018517419A (ja) 2018-07-05
RU2018101722A3 (enExample) 2019-12-10
AU2016278588B2 (en) 2022-03-31
LT3310379T (lt) 2019-12-27
EP3626262C0 (en) 2024-10-23
CA2989247C (en) 2023-10-17
SI3310379T1 (sl) 2020-02-28
ES2994561T3 (en) 2025-01-27
MX2017016183A (es) 2018-06-19
HK1252435A1 (en) 2019-05-24
CA2989247A1 (en) 2016-12-22
AU2016278588A1 (en) 2017-12-21
EP3626262A1 (en) 2020-03-25
EP3626262B1 (en) 2024-10-23
EP3310379B1 (en) 2019-11-06
RU2018101722A (ru) 2019-07-18
ZA201708439B (en) 2021-05-26
US20210077605A1 (en) 2021-03-18
BR112017027378A2 (pt) 2018-08-28
IL256076A (en) 2018-01-31
US10905752B2 (en) 2021-02-02
ES2760699T3 (es) 2020-05-14
WO2016202459A1 (en) 2016-12-22
KR20180037948A (ko) 2018-04-13

Similar Documents

Publication Publication Date Title
US10293037B2 (en) DNA vaccine for use in pancreatic cancer patients
JP6947649B2 (ja) 複合治療のためのｖｅｇｆｒ−２標的化ｄｎａワクチン
JP7247097B2 (ja) がん免疫療法のための新規ｐｄ－ｌ１標的ｄｎａワクチン
JP2023160838A (ja) 新規ｖｅｇｆｒ－２ターゲット免疫療法アプローチ
JP2019533698A (ja) 併用療法のためのｗｔ１標的指向性ｄｎａワクチン
HK40026195A (en) Vegfr-2 targeting dna vaccine for combination therapy
HK40026195B (en) Vegfr-2 targeting dna vaccine for combination therapy
HK1252435B (en) Vegfr-2 targeting dna vaccine for combination therapy
JP2023510770A (ja) 抗生剤と組み合わせた、サルモネラベースのｄｎａワクチン

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190418

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200303

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210727

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210817

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210916

R150 Certificate of patent or registration of utility model

Ref document number: 6947649

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250